Hikma Pharmaceuticals (HIK) Stock Statistics & Valuation Metrics

Hikma Pharmaceuticals has a market cap or net worth of £3.93B. The enterprise value is 5.40B.

Hikma Pharmaceuticals has 221,886,460 shares outstanding. The number of shares has decreased by -2.65% in one year.

Hikma Pharmaceuticals’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 12.79%.

The current PE Ratio of Hikma Pharmaceuticals is 13.8. Hikma Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Hikma Pharmaceuticals had revenue of 3.13B and earned 359.00M in profits. Earnings per share was 1.61.

In the last 12 months, operating cash flow was 366.00M and capital expenditures -82.00M, giving a free cash flow of 284.00M billion.

Hikma Pharmaceuticals pays an annual dividend of 26.516p, resulting in a dividend yield of 3.55%

Hikma Pharmaceuticals upcoming earnings date is Feb 19, 2026, TBA (Confirmed).

Hikma Pharmaceuticals as a current ratio of 1.14, with Debt / Equity ratio of 56.54%

In the past 12 months, Hikma Pharmaceuticals has paid 93.00M in taxes.

Hikma Pharmaceuticals EV to EBITDA ratio is 8.49, with an EV/FCF ratio of 16.74.

Hikma Pharmaceuticals has £213.00M in cash and marketable securities with £1.31B in debt, giving a net cash position of £1.09B billion.

Gross margin is 45.25%, with operating margin of 19.57%, and net profit margin of 11.48%.

The average price target for Hikma Pharmaceuticals is £2,466.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy